SonoThera
Develops ultrasound-mediated nonviral genetic medicines
$125MSeries B
Role not disclosedME
Medical Excellence Capital
Activity from announced rounds
Activity in this selectionUnited States · Jun 30, 2026 · Jun 1, 2026
Medical Excellence Capital is the investment firm named in SonoThera and TwoStep financing histories.
Recorded funding activity
SonoThera develops ultrasound-mediated delivery of genetic medicines. TwoStep develops peptide-targeted therapies for solid tumors. These companies pursue different mechanisms of treatment, with uncertain financing roles preserved rather than inferred.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $125M 1 disclosed · full round size, not this investor’s share